The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Health-related quality of life (HRQOL) in the phase 3 trial of cabozantinib vs placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy (CABINET, Alliance A021602).
 
Amylou Dueck
Honoraria - Novartis
 
Briant Fruth
No Relationships to Disclose
 
Susan Geyer
No Relationships to Disclose
 
Tyler Zemla
No Relationships to Disclose
 
Sydney Pulsipher
No Relationships to Disclose
 
Fang-Shu Ou
No Relationships to Disclose
 
Jared Acoba
Consulting or Advisory Role - GlaxoSmithKline
Research Funding - GlaxoSmithKline
 
Ardaman Shergill
Honoraria - Biyantara Foundation; Cholangiocarcinoma Foundation; Colon Cancer Alliance; Colon Cancer alliance; Great Debates in GI cancers
Consulting or Advisory Role - Guardant Health; Ipsen; Iterion Therapeutics; Merus; Pfizer; Pfizer; Revolution Medicines; Takeda
Research Funding - Abbvie (Inst); Arcus Biosciences (Inst); Astellas Pharma (Inst); BMS (Inst); Clovis Oncology (Inst); Daiichi Sankyo (Inst); Genentech (Inst); Gossamer Bio (Inst); Gritstone Bio (Inst); Hutchison MediPharma (Inst); Macrogenics (Inst); Merck (Inst); Oncologie (Inst); Pfizer (Inst); Pfizer (Inst); Seattle Genetics/Astellas (Inst); Seattle Genetics/Astellas (Inst); Takeda (Inst); TP Therapeutics (Inst); verastem (Inst)
Travel, Accommodations, Expenses - colon cancer alliance; Ipsen; Merus; Revolution Medicines; Takeda
 
Edward Wolin
Consulting or Advisory Role - AlphaMedix; Exelixis
 
Thorvardur Halfdanarson
Consulting or Advisory Role - Advanced Accelerator Applications (Inst); Biomea Fusion; Boehringer Ingelheim; Camurus (Inst); Crinetics Pharmaceuticals (Inst); Curium Pharma; Exelixis; Ipsen (Inst); ITM Isotope Technologies Munich (Inst); Perspective Therapeutics (Inst); Tersera; Viewpoint Molecular Targeting (Inst)
Research Funding - Advanced Accelerator Applications (Inst); Camurus (Inst); Crinetics Pharmaceuticals (Inst); ITM Isotope Technologies Munich (Inst); Novartis (Inst); Perspective Therapeutics (Inst); Thermo Fisher Scientific (Inst); Turnstone Bio (Inst)
(OPTIONAL) Uncompensated Relationships - North American Neuroendocrine Tumor Society
 
Bhavana Konda
Research Funding - Eisai (Inst); Lilly (Inst); Merck (Inst); Xencor (Inst)
 
Nikolaos Trikalinos
Research Funding - Bristol-Myers Squibb (Inst); Elevar Therapeutics (Inst); Exelixis (Inst); Merck (Inst); Novartis (Inst); Nykode Therapeutics (Inst)
 
Shagufta Shaheen
Consulting or Advisory Role - Crinetics Pharmaceuticals; Exelixis; Project in Knowledge
Travel, Accommodations, Expenses - Dava Oncology
 
Namrata Vijayvergia
Honoraria - Guidepoint Global
Consulting or Advisory Role - Exelixis; Pfizer; RayzeBio
Research Funding - Bristol-Myers Squibb/Medarex (Inst); ITM Isotope Technologies Munich (Inst); Oryzon Genomics (Inst); Puma Biotechnology (Inst); Zymeworks (Inst)
 
Arvind Dasari
Consulting or Advisory Role - HutcMed; Illumina/GRAIL; Personalis; SIRTIS; Takeda
Research Funding - Eisai (Inst); Guardant Health (Inst); Hutchison MediPharma (Inst); Merck (Inst); Natera (Inst); XENCOR (Inst)
Travel, Accommodations, Expenses - Hutchison MediPharma; Takeda
 
Jonathan Strosberg
Consulting or Advisory Role - Boehringer Ingelheim; Exelixis
Research Funding - Alphamedix (Inst); ITM Solucin (Inst); Novartis (Inst); RayzeBio (Inst)
 
Eileen O'Reilly
Consulting or Advisory Role - Abbvie (I); AstraZeneca; Autem Medical (I); Berry Genomics (I); BioNTech SE; Boehringer Ingelheim; Bristol-Myers Squibb/Celgene; Eisai (I); Exelixis (I); Genentech/Roche (I); Ipsen; J-Pharma (I); Merck; Merus; Novartis; QED Therapeutics (I); Revolution Medicines; SERVIER (I); Vector Health (I); Yiviva (I)
Research Funding - Agenus (Inst); Arcus Ventures (Inst); AstraZeneca/MedImmune (Inst); BioNTech (Inst); Bristol Myers Squibb (Inst); Digestive Care (Inst); Elicio Therapeutics (Inst); Genentech (Inst); Helsinn Healthcare (Inst); Parker Institute for Cancer Immunotherapy (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst); Revolution Medicines (Inst); Yiviva (Inst)
(OPTIONAL) Uncompensated Relationships - Thetis Pharma
 
Jeffrey Meyerhardt
Employment - Dana-Farber Cancer Institute; Newton Wellesley Hospital (I)
Speakers' Bureau - Research to Practice
 
Jennifer Chan
Stock and Other Ownership Interests - Merck
Consulting or Advisory Role - Boehringer Ingelheim; Curium Pharma; Ipsen; Lantheus Medical Imaging; Novartis; Pfizer (I)
Research Funding - Lilly (Inst)
Patents, Royalties, Other Intellectual Property - Royalties from UpToDate for authorship
(OPTIONAL) Uncompensated Relationships - Camurus